Carcinoma of the gastroesophageal junction in Chinese patients
- PMID: 23326117
- PMCID: PMC3544014
- DOI: 10.3748/wjg.v18.i48.7134
Carcinoma of the gastroesophageal junction in Chinese patients
Abstract
Carcinoma of the gastroesophageal junction (GEJ) is defined as carcinoma that crosses the GEJ line, irrespective of where the tumor epicenter is located. This group of cancer is rare but controversial. Based on study results from the majority of epidemiologic and clinicopathologic investigations carried out in Western countries, this cancer is believed to arise from Barrett's esophagus (BE) and includes both distal esophageal and proximal gastric carcinomas because of similar characteristics in epidemiology, clinicopathology, and molecular pathobiology in relation to BE. As such, the most recent American Joint Committee on Cancer staging manual requires staging all GEJ carcinomas with the rule for esophageal adenocarcinoma (EA). This mandate has been challenged recently by the data from several studies carried out mainly in Chinese patients. The emerging evidence derived from those studies suggests: (1) both BE and EA are uncommon in the Chinese population; (2) almost all GEJ cancers in Chinese arise in the proximal stomach and show the features of proximal gastric cancer, not those of EA; (3) application of the new cancer staging rule to GEJ cancer of Chinese patients cannot stratify patients' prognosis effectively; and (4) prognostic factors of GEJ cancer in Chinese are similar, but not identical, to those of EA. In conclusion, the recent evidence suggests that GEJ cancer in Chinese shows distinct clinicopathologic characteristics that are different from EA. Further investigations in molecular pathology may help illustrate the underlying pathogenesis mechanisms of this cancer in Chinese patients and better manage patients with this fatal disease.
Keywords: Barrett’s esophagus; Cancer; Esophagus; Gastroesophageal junction; Staging; Stomach.
Similar articles
-
Comparison of gastro-oesophageal junction carcinomas in Chinese versus American patients.Histopathology. 2011 Aug;59(2):188-97. doi: 10.1111/j.1365-2559.2011.03924.x. Histopathology. 2011. PMID: 21884197
-
Intestinal metaplasia around the gastroesophageal junction is frequently associated with antral reactive gastropathy: implications for carcinoma at the gastroesophageal junction.Hum Pathol. 2020 Nov;105:67-73. doi: 10.1016/j.humpath.2020.08.007. Epub 2020 Sep 14. Hum Pathol. 2020. PMID: 32941964 Free PMC article.
-
Different histological status of gastritis in superficial adenocarcinoma of the esophagogastric junction.Jpn J Clin Oncol. 2014 Jan;44(1):65-71. doi: 10.1093/jjco/hyt167. Epub 2013 Nov 11. Jpn J Clin Oncol. 2014. PMID: 24220802
-
Adenocarcinoma of the GEJ: gastric or oesophageal cancer?Recent Results Cancer Res. 2012;196:107-13. doi: 10.1007/978-3-642-31629-6_7. Recent Results Cancer Res. 2012. PMID: 23129369 Review.
-
Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers.J Natl Compr Canc Netw. 2013 Jan 1;11(1):60-6. doi: 10.6004/jnccn.2013.0009. J Natl Compr Canc Netw. 2013. PMID: 23307982 Review.
Cited by
-
Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconstruction after gastrectomy for Siewert types II and III adenocarcinoma of the esophagogastric junction.World J Gastroenterol. 2015 Sep 14;21(34):9999-10007. doi: 10.3748/wjg.v21.i34.9999. World J Gastroenterol. 2015. PMID: 26379405 Free PMC article.
-
Clinical and prognostic features of MMP-2 and VEGF in AEG patients.Open Med (Wars). 2021 May 14;16(1):786-794. doi: 10.1515/med-2021-0252. eCollection 2021. Open Med (Wars). 2021. PMID: 34027107 Free PMC article.
-
Obesity and related risk factors in gastric cardia adenocarcinoma.Gastric Cancer. 2015 Jan;18(1):23-32. doi: 10.1007/s10120-014-0425-4. Epub 2014 Sep 11. Gastric Cancer. 2015. PMID: 25209115 Review.
-
Golgi scaffold protein PAQR3 as a candidate suppressor of gastric cardia adenocarcinoma via regulating TGF-β/Smad pathway.J Clin Lab Anal. 2022 Sep;36(9):e24617. doi: 10.1002/jcla.24617. Epub 2022 Jul 23. J Clin Lab Anal. 2022. PMID: 35870178 Free PMC article.
-
SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma.Front Immunol. 2022 Aug 16;13:977894. doi: 10.3389/fimmu.2022.977894. eCollection 2022. Front Immunol. 2022. PMID: 36052090 Free PMC article.
References
-
- Odze RD, Flejou JF, Boffetta P, Hofler H, Montgomery E, Spechler SJ. Adenocarcinoma of the oesophgogastric junction. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO Classification of Tumours of the Digestive System, World Health Organization Classification of Tumours, Lyon: IARC Press; 2010. pp. 39–44.
-
- Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457–1459. - PubMed
-
- Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophago-gastric junction. Scand J Surg. 2006;95:260–269. - PubMed
-
- McColl KE, Going JJ. Aetiology and classification of adenocarcinoma of the gastro-oesophageal junction/cardia. Gut. 2010;59:282–284. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials